IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
Phase 2/3 oncology biotech developing engineered antibody-drug conjugates.
Industry: Health Care
Latest Trade: $28.00 0.00 (0.0%)
First Day Return: -5.3%
Return from IPO: +55.6%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 05/28/2021 |
Offer Price | $18.00 |
Price Range $17.00 - $19.00 | |
Offer Shares (mm) | 7.0 |
Deal Size ($mm) | $126 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 06/17/2021 |
Offer Price | $18.00 |
Price Range $17.00 - $19.00 | |
Offer Shares (mm) | 7.0 |
Deal Size ($mm) | $126 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
Goldman Sachs |
BofA Securities |
more |
Company Data | |
---|---|
Headquarters | La Jolla, CA, United States |
Founded | 2003 |
Employees | 70 |
Website www.ambrx.com |